PDX Models From EGFR Mutant Tumors

Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression

NCT02431169 ·Status: TERMINATED

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

NCT02488694 ·Status: TERMINATED ·Phase: PHASE2

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638 ·Status: UNKNOWN

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142 ·Status: RECRUITING ·Phase: PHASE3

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

NCT06247826 ·Status: RECRUITING ·Phase: NA

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

NCT04122833 ·Status: UNKNOWN

Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer

NCT00899756 ·Status: COMPLETED

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 ·Status: UNKNOWN

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

NCT06418412 ·Status: RECRUITING

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

NCT03127449 ·Status: TERMINATED ·Phase: NA

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

NCT02178397 ·Status: TERMINATED ·Phase: PHASE3

A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer

NCT01100840 ·Status: UNKNOWN

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

NCT02705339 ·Status: WITHDRAWN ·Phase: PHASE2

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

NCT03137264 ·Status: COMPLETED

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)

NCT02293733 ·Status: COMPLETED

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

NCT02973763 ·Status: TERMINATED ·Phase: PHASE1

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

NCT02804776 ·Status: COMPLETED ·Phase: PHASE2

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

NCT06463171 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Acquired Resistant Mechanism of the First-generation EGFR TKIs

NCT02804217 ·Status: UNKNOWN

A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

NCT05419700 ·Status: COMPLETED

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

NCT02353741 ·Status: TERMINATED ·Phase: PHASE2

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

NCT05514314 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)

NCT05737849 ·Status: WITHDRAWN

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

NCT02299765 ·Status: TERMINATED ·Phase: PHASE4